Small Stocks, Big Money™

Atossa Therapeutics (Nasdaq: ATOS) introduced a landmark Phase 3 study proposal—SMART 2.0—at AACR 2025, aiming to evaluate its proprietary low-dose oral (Z)-endoxifen in reducing aggressive interval breast cancers in high-risk women. Backed by promising Phase 2 results showing a 20% reduction in mammographic density with minimal side effects, the trial could position (Z)-endoxifen as a first-of-its-kind preventative treatment targeting breast cancer risk factors through AI-driven screening.

Venu Holding Corporation (NYSE American: VENU) has received El Paso City Council approval for an expanded development agreement, unlocking a $100M+ investment in its 12,500-seat Sunset Amphitheater project. With a projected $2B economic impact over the next decade, the company is also launching Luxe FireSuites—a premium fractional ownership opportunity offering elite access and long-term returns in the region’s next landmark entertainment destination.

ConnectM Technology Solutions (Nasdaq: CNTM) reported that the investor group behind the $1.60 per share non-binding buy-out proposal now holds 31.4% of the company’s outstanding shares, signaling growing commitment to the acquisition. While the board continues to evaluate the offer, the group’s increased ownership adds momentum to the potential deal for the energy tech innovator.

SRx Health Solutions (NYSE American: SRXH) announced plans to explore allocating up to 10% of future cash flows and reserves into Bitcoin, Solana, and precious metals—aiming to enhance capital preservation and shareholder value. The move reflects SRx’s forward-looking cash management strategy amid evolving macroeconomic conditions.